Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B.

Zhu S, Dong Y, Wang L, Liu W, Zhao P.

J Hepatol. 2019 Jun 19. pii: S0168-8278(19)30356-3. doi: 10.1016/j.jhep.2019.06.009. [Epub ahead of print]

PMID:
31228491
2.

A 3-year clinical trial of lamivudine in treatment of patients with chronic hepatitis B.

Yao GB, Cui ZY, Wang BE, Yao JL, Zeng MD.

Hepatobiliary Pancreat Dis Int. 2004 May;3(2):188-93.

3.

[A retrospective study on HBsAg clearance rate after antiviral therapy in children with HBeAg-positive chronic hepatitis B aged 1-7 years].

Zhu SS, Dong Y, Xu ZQ, Wang LM, Chen DW, Gan Y, Wang FC, Yan JG, Cao LL, Wang P, Zhang HF.

Zhonghua Gan Zang Bing Za Zhi. 2016 Oct 20;24(10):738-743. doi: 10.3760/cma.j.issn.1007-3418.2016.10.005. Chinese.

PMID:
27938558
4.

Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort.

Wiegand J, Brosteanu O, Kullig U, Wiese M, Berr F, Maier M, Tillmann HL, Schiefke I.

Z Gastroenterol. 2011 Nov;49(11):1463-9. doi: 10.1055/s-0031-1281582. Epub 2011 Nov 8.

PMID:
22069045
5.

[The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].

Yao GB, Wang BE, Cui ZY, Yao JL, Zeng MD.

Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):382-7. Chinese.

PMID:
12895320
6.

[Clinical study on blocking mother-to-child transmission of hepatitis B virus with high viral load and HBeAg positivity during pregnancy in Guizhou province].

Zhang BF, Cheng ML, Zhang Q, Zhao XK, Yu L, Yang J, Deng KS, Zhang LS, Wang J, Hu YX.

Zhonghua Gan Zang Bing Za Zhi. 2018 Dec 20;26(12):945-950. doi: 10.3760/cma.j.issn.1007-3418.2018.12.013. Chinese.

PMID:
30669789
7.

Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.

Wong RJ, Nguyen MT, Trinh HN, Chan C, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Torres S, Yang J, Liu B, Garcia RT, Bhuket T, Baden R, Levitt B, da Silveira E, Gish RG.

J Viral Hepat. 2017 Dec;24(12):1089-1097. doi: 10.1111/jvh.12736. Epub 2017 Jul 29.

PMID:
28581644
8.

Mother-to-child transmission of hepatitis B: Examining viral cut-offs, maternal HBsAg serology and infant testing.

Thilakanathan C, Wark G, Maley M, Davison S, Lawler J, Lee A, Shackel N, Nguyen V, Jackson K, Glass A, Locarnini SA, Levy MT.

Liver Int. 2018 Jul;38(7):1212-1219. doi: 10.1111/liv.13736. Epub 2018 Mar 31.

PMID:
29532580
9.

Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.

Zhu S, Zhang H, Dong Y, Wang L, Xu Z, Liu W, Gan Y, Tang H, Chen D, Wang F, Zhao P.

J Hepatol. 2018 Jun;68(6):1123-1128. doi: 10.1016/j.jhep.2018.01.037. Epub 2018 Feb 13.

PMID:
29452204
10.

Treatment of chronic hepatitis B: case selection and duration of therapy.

Leung N.

J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. Review.

PMID:
11982721
11.

A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus.

Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW.

World J Gastroenterol. 2011 Oct 14;17(38):4321-33. doi: 10.3748/wjg.v17.i38.4321.

12.

[A retrospective study on the liver pathological characteristics and the effect of antiviral treatment for 1 to 7 years old children with heptitis B e antigen negative chronic hepatitis B].

Zhu SS, Dong Y, Wang LM, Xu ZQ, Chen DW, Gan Y, Wang FC, Yan JG, Cao LL, Wang P, Zhang M, Zhang HF.

Zhonghua Er Ke Za Zhi. 2016 Aug;54(8):587-91. doi: 10.3760/cma.j.issn.0578-1310.2016.08.006. Chinese.

PMID:
27510870
13.

The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment.

Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM.

J Hepatol. 2014 Sep;61(3):515-22. doi: 10.1016/j.jhep.2014.04.029. Epub 2014 May 2.

PMID:
24798617
14.

Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.

Chen J, Wang Z, Zhou B, Wang Y, Hou J.

Antivir Ther. 2012;17(1):71-9. doi: 10.3851/IMP1925.

PMID:
22267471
15.

Efficacy of Antiviral Therapy in HBsAg-Positive Pregnant Women to Reduce Mother-to-Infant Transmission of Hepatitis B Virus.

Chandran JR, Raj SV.

J Obstet Gynaecol India. 2018 Oct;68(5):355-359. doi: 10.1007/s13224-017-1044-x. Epub 2017 Sep 9.

PMID:
30224838
16.

An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.

Yao G, Cui Z, Wang B, Yao J, Zeng M.

Chin Med J (Engl). 2002 Dec;115(12):1814-8.

PMID:
12622930
17.

Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B.

Lee HL, Jang JW, Han JW, Lee SW, Bae SH, Choi JY, Han NI, Yoon SK, Kim HJ, Lee S, Cho SG, Min CK, Kim DW, Lee JW.

Dig Dis Sci. 2019 Apr 13. doi: 10.1007/s10620-019-05614-6. [Epub ahead of print]

PMID:
30982209
18.

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.

Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF.

J Hepatol. 2013 Oct;59(4):709-16. doi: 10.1016/j.jhep.2013.06.007. Epub 2013 Jun 17.

PMID:
23792029
19.

Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.

Liao YP, Jiang JL, Zou WY, Xu DR, Li J.

World J Gastroenterol. 2015 Apr 14;21(14):4284-92. doi: 10.3748/wjg.v21.i14.4284.

20.

A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.

Yalçin K, Değertekin H, Kokoğlu OF, Ayaz C.

Turk J Gastroenterol. 2004 Mar;15(1):14-20.

Supplemental Content

Support Center